GSK PLC Sponsored ADR Announces Quarterly Dividend of $0.44 (NYSE:GSK)

Key Points

• GSK announced a quarterly dividend of $0.44 per ADR, payable July 9 to shareholders of record on May 15, implying a 3.4% yield and an annualized dividend of $1.88.
• The dividend appears well covered with a current payout ratio of about 38.8% and analysts forecasting ~$5.09 EPS next year (implied future payout ~36.9%), despite a slight average dividend decline over the past three years.
• In the latest quarter GSK reported $0.68 EPS (beating the $0.64 estimate) and revenue of $11.59 billion (up 6.2% year‑over‑year), signaling solid near‑term operational performance.

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) announced a quarterly dividend on Wednesday, April 29th. Shareholders of record on Friday, May 15th will be given a dividend of 0.44 per share by the pharmaceutical company on Thursday, July 9th. This represents a c) annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Friday, May 15th.

GSK has decreased its dividend payment by an average of 0.1%annually over the last three years. GSK has a dividend payout ratio of 38.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect GSK to earn $5.09 per share next year, which means the company should continue to be able to cover its $1.88 annual dividend with an expected future payout ratio of 36.9%.

GSK Stock Performance

NYSE GSK opened at $51.65 on Friday. The firm has a market capitalization of $104.81 billion, a P/E ratio of 13.42, a PEG ratio of 2.98 and a beta of 0.46. The stock has a 50-day simple moving average of $55.78 and a two-hundred day simple moving average of $51.62. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.54 and a current ratio of 0.82. GSK has a fifty-two week low of $35.45 and a fifty-two week high of $61.69.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Thursday, February 5th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.04. The company had revenue of $11.59 billion during the quarter, compared to the consensus estimate of $8.48 billion. GSK had a return on equity of 45.90% and a net margin of 17.82%.GSK's revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.23 earnings per share. On average, equities analysts forecast that GSK will post 4.88 earnings per share for the current year.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK's core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.